Forest Laboratories Inc. (FRX)
-NYSE 37.92 
0.06(0.16%) 4:01PM EDT|After Hours
:
37.92 0.00 (0.00%) 4:25PM EDT
| Prev Close: | 37.98 |
|---|
| Open: | 37.96 |
|---|
| Bid: | 37.75 x 200 |
|---|
| Ask: | 38.12 x 200 |
|---|
| 1y Target Est: | 38.29 |
|---|
| Beta: | 0.55 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 37.69 - 38.07 |
|---|
| 52wk Range: | 31.28 - 39.09 |
|---|
| Volume: | 665,433 |
|---|
| Avg Vol (3m): | 1,328,180 |
|---|
| Market Cap: | 10.10B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.12 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatideat Seeking Alpha(Tue 1:41PM EDT)
- Is There a Pill For That? Forest Labs’ Iffy PipelineYCharts(Tue 9:27AM EDT)
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’at Bloomberg(Mon, May 20)
- July Options Now Available For Forest Laboratories (FRX)at TheStreet(Mon, May 20)
- Forest to Present Aclidinium Bromide and Roflumilast Clinical Data at the American Thoracic Society (ATS) International ConferenceBusiness Wire(Fri, May 17)
- Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund, Interviews with The Wall Street Transcript: Investing in Health Care InnovationWall Street Transcript(Thu, May 16)
- Forest Laboratories, Inc. to Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual MeetingBusiness Wire(Thu, May 16)
- Forest Reaches New 52-Week High (FRX)at TheStreet(Tue, May 14)
- Forest-Trevena Ink DealZacks(Tue, May 14)
- Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013Business Wire(Tue, May 14)
- Europe Eases Corporate Tax Dodge as Worker Burdens Riseat Bloomberg(Mon, May 13)
- Analyst Moves: MU, FRX, AES, CVCat Forbes(Fri, May 10)
- Analysts' Actions: MU BSX CVC FRXat TheStreet(Fri, May 10)
- Trevena Inc. and Forest Laboratories Announce a Collaborative Agreement for Development of TRV027 for the Treatment of Acute Heart FailureBusiness Wire(Thu, May 9)
- Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart FailurePR Newswire(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | 24.31 |
|---|
| P/S (ttm): | 3.27 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Mar-14)
: | 0.88 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.11 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | 1.27 |
|---|
Business Summary
Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. It principally offers Namenda for the treatment of moderate and severe Alzheimer's disease; Bystolic...
View More